Partner: Formulate healthcare investment strategy, focusing on biotech and diagnostics investment, deal sourcing, financial modeling, investor screening, deal negotiation, and post-investment management;

Director of Strategy: Formulate overall strategy in product development, operation optimization, marketing, and market access, ;Director of Business Development: Approach, evaluate potential partners in diagnostic device and licensing with pharmaceuticals, negotiate business terms for business collaboration and VC financing;Director of Public Relations: Development media relations to promote corporate image, to facilitate product marketing and build branding among customers, collaborators, potential employees, and investors.

Produt Portfolio and Strategy: Drug pre-launch planning through inter-departmental work streams to analyze disease burden and treatment gap, increase disease awareness, and accelerate regulatory approvalProject Management Office: Optimized purchase order system and reduced payment cycle through intra-department collaboration to increase financial system efficiency and improve vendor relationshipProject Management Office: Created internal collaboration between Global Clinical Research/Regional Clinical Operation/Global Medical Affairs for knowledge exchange, clinical trial facilitation, and talent transfer

Investigated and conducted field work on healthcare sector investment candidates for deal sourcing, focusing on biotech, pharmaceutical, and medical devices, and formulated strategy advice to firm partners. Evaluated business plans, communicated with prospective portfolio companies to perform due diligence and risk assessment, draft term sheets and make recommendation to investment committee.

Researched over 150 protein drugs for bio-similar business opportunities to expand biogeneric pipeline, demonstrated to company management 4 potent candidates, including 2 mono-clonal antibodies and 2 recombinant protein drugs in lymphoma, auto-immune disease, diabetes, and erythropoiesis-stimulation indication areasSupported by the National Significant Pioneer Drug Project application in Jiangsu province, integrated 7.8 million RMB R&D cost into 2012 budget, secured long-term investment from parent company and government fundingBuilt company core R&D force by recruiting 20 researchers, and mentored 4 teams in cancer, diabetes, vet medicine, and IVD areas. Defined internal regulations by establishing performance review and experiment SOPsDeveloped anti-tumor drug early research project with cross-continent team, designed 2 sets of drug delivery strategy that targets different novel surface markers on cancer cells, achieved research milestone in 6 months

Oversaw and reduced laboratory budget by average 27%, and maintained project performances and time linesPerformed early pulmonary drug discovery by High Throughput Screening (HTS) using mammalian cell modelLed early product R&D effort of PCR based medical device and designed preliminary clinical trial for aerosolinfectious disease detection, reduced neonatal mortality caused by respiratory disease for over 20%Isolated, identified, screened, and induced bone marrow stem cells from rat pups for regenerative medicine research

Reviewed and revised Quality System Manual, Device Master Record for dental implant device.Validated manufacturing process and verified product specifications to meet standards.Participated in manufacturing activity, re-designed key equipments to improve efficiency and maintain quality.Reviewed product labeling design and ensure compliance with FDA guidance.

Analyzed financial performance of public traded companies in biotech and pharmaceutical industry sector, using regulatory and biotech expertise to investigate product development and competitive advantages Compiled investment reports on quarterly basis for the firm and US/China investors

Gave lab lectures, supervised lab sessions, held office hours to answer students’ questions, designed exam questions, and graded exams in the classes of Molecular Biology, Microbiology, and Biochemistry.

PdL conditional mutation system and tet-on over expression system in Drosophila melanogaster. Selective gene over expression and screening for Drosophila aging and fertility related regulator genes.Identification of Drosophila midgut stem cells and stem specific genes.

Oversaw mock IRB to evaluate protocol design and informed consent for phase II Citalopram trial.Prepared IRB response letter and presented it before sponsor to explain deferment decision.Revised design of type II diabetes drug multi-center trial, minimized culture impact on reliability of data output.Corrected 3 unethical trials by using 3 criteria of Belmont Report to ensure regulatory compliance.Recruited 3 candidate clinical sites for GI study, minimized trial costs and number of required patients.Examined API DMF for completeness, complemented missing parts and trimmed off unnecessary information.Created CMC report outline for generic phase III trial report and followed requirements of CTD format.Designed regulatory strategy to develop generic of blockbuster drug by applying 505 (b)(2) pathway.